RESEARCH NEWS

Cell cycle (Georgetown, Tex.) · 2026-12-01

Stattic administration plays a protective role in a lipopolysaccharide-induced acute lung injury cell model.

Researchers studying NAD+ published a paper titled "Stattic administration plays a protective role in a lipopolysaccharide-induced acute lung injury cell model." in Cell cycle (Georgetown, Tex.) (2026 Dec). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Trends in biotechnology · 2026-06-19

Reprogramming bacterial energetics reverses lactate-mediated immunosuppression for synergistic cancer immunotherapy.

Researchers studying NAD+ published a paper titled "Reprogramming bacterial energetics reverses lactate-mediated immunosuppression for synergistic cancer immunotherapy." in Trends in biotechnology (2026 Jun 19). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-06-19

Gut microbiome signatures discriminate deep vein thrombosis through machine learning and metabolic analysis.

Researchers studying NAD+ published a paper titled "Gut microbiome signatures discriminate deep vein thrombosis through machine learning and metabolic analysis." in Scientific reports (2026 Jun 19). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Experimental physiology · 2026-06-19

Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model.

Researchers studying MOTS-c published a paper titled "Mitochondrial peptide MOTS-c suppresses systemic and cardiac inflammasome activation in a diabetic rat model." in Experimental physiology (2026 Jun 19). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: MOTS-C

Nature communications · 2026-06-19

Molecular mechanisms of transhydrogenase activity and allosteric regulation in eukaryotic type II PHGDH Ser33.

Researchers studying NAD+ published a paper titled "Molecular mechanisms of transhydrogenase activity and allosteric regulation in eukaryotic type II PHGDH Ser33." in Nature communications (2026 Jun 19). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026-06-19

A juglone derivative that disrupts mitochondrial redox metabolism, inhibiting the breast fibroblast-cancer cell pro-migratory signaling induced by doxorubicin.

Researchers studying NAD+ published a paper titled "A juglone derivative that disrupts mitochondrial redox metabolism, inhibiting the breast fibroblast-cancer cell pro-migratory signaling induced by doxorubicin." in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026 Jun 19). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Redox biology · 2026-06-18

Redox imbalance dictates dependence on GOT1 versus GOT2 for rod photoreceptor health during aging and stress.

Researchers studying NAD+ published a paper titled "Redox imbalance dictates dependence on GOT1 versus GOT2 for rod photoreceptor health during aging and stress." in Redox biology (2026 Jun 18). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of bacteriology · 2026-06-18

Adaptive evolution of electron transfer pathways in Thermoanaerobacterium saccharolyticum.

Researchers studying NAD+ published a paper titled "Adaptive evolution of electron transfer pathways in Thermoanaerobacterium saccharolyticum." in Journal of bacteriology (2026 Jun 18). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Tissue & cell · 2026-06-18

Tartary Buckwheat protein-derived peptide AFYRW alleviates H₂O₂-induced inflammation and apoptosis in HaCaT cells by activating SIRT1-dependent deacetylation.

Researchers studying NAD+ published a paper titled "Tartary Buckwheat protein-derived peptide AFYRW alleviates H₂O₂-induced inflammation and apoptosis in HaCaT cells by activating SIRT1-dependent deacetylation." in Tissue & cell (2026 Jun 18). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chemistry (Weinheim an der Bergstrasse, Germany) · 2026-06-18

Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.

Researchers studying GLP-1 / GLUCAGON DUAL AGONIST published a paper titled "Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics." in Chemistry (Weinheim an der Bergstrasse, Germany) (2026 Jun 18). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST

Arthritis research & therapy · 2026-06-18

The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide.

Researchers studying NAD+ published a paper titled "The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide." in Arthritis research & therapy (2026 Jun 18). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Stem cell reviews and reports · 2026-06-17

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges.

Researchers studying NAD+ published a paper titled "Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges." in Stem cell reviews and reports (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Phytopathology · 2026-06-17

Fluoxastrobin Targets NAD[P]H:quinone oxidoreductase to Disrupt Membrane Redox Balance and Suppress Lasiodiplodia theobromae, an Emerging Tea Pathogen.

Researchers studying NAD+ published a paper titled "Fluoxastrobin Targets NAD[P]H:quinone oxidoreductase to Disrupt Membrane Redox Balance and Suppress Lasiodiplodia theobromae, an Emerging Tea Pathogen." in Phytopathology (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Virulence · 2026-06-17

Targeting metabolism and membrane: Neferine synergizes with gentamicin against Escherichia coli by disrupting FNR/ArcA-Mediated homeostasis.

Researchers studying NAD+ published a paper titled "Targeting metabolism and membrane: Neferine synergizes with gentamicin against Escherichia coli by disrupting FNR/ArcA-Mediated homeostasis." in Virulence (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

ACS chemical neuroscience · 2026-06-17

Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.

Researchers studying GLP-1 / GLUCAGON DUAL AGONIST published a paper titled "Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine." in ACS chemical neuroscience (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST

Functional & integrative genomics · 2026-06-17

MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy.

Researchers studying NAD+ published a paper titled "MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy." in Functional & integrative genomics (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biomarker research · 2026-06-17

NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS.

Researchers studying NAD+ published a paper titled "NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS." in Biomarker research (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

The Journal of clinical endocrinology and metabolism · 2026-06-17

Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures.

Researchers studying GLP-1 / GLUCAGON DUAL AGONIST published a paper titled "Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures." in The Journal of clinical endocrinology and metabolism (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST

Chemico-biological interactions · 2026-06-17

Resorufin-derived esters as fluorescent probes to test for the esterase activity and active-site topology of aldehyde dehydrogenase.

Researchers studying NAD+ published a paper titled "Resorufin-derived esters as fluorescent probes to test for the esterase activity and active-site topology of aldehyde dehydrogenase." in Chemico-biological interactions (2026 Jun 17). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-06-16

Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men.

Researchers studying NAD+ published a paper titled "Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men." in Scientific reports (2026 Jun 16). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-06-16

The effect of Staphylococcus aureus targeting ROS-dependent mitochondrial damage activating NLRP10 in inducing skin and soft tissue infection.

Researchers studying NAD+ published a paper titled "The effect of Staphylococcus aureus targeting ROS-dependent mitochondrial damage activating NLRP10 in inducing skin and soft tissue infection." in Scientific reports (2026 Jun 16). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

ACS applied materials & interfaces · 2026-06-16

Compartmentalized Encapsulation of Rhodium-Alginate Conjugate in Hybrid Hydrogen-Bonded Organic Frameworks for In Situ Cofactor Recycling and Biocatalysis.

Researchers studying NAD+ published a paper titled "Compartmentalized Encapsulation of Rhodium-Alginate Conjugate in Hybrid Hydrogen-Bonded Organic Frameworks for In Situ Cofactor Recycling and Biocatalysis." in ACS applied materials & interfaces (2026 Jun 16). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cell reports. Medicine · 2026-06-16

Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy.

Researchers studying NAD+ published a paper titled "Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy." in Cell reports. Medicine (2026 Jun 16). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of virology · 2026-06-15

The nicotinamide phosphoribosyltransferase inhibitor FK866 restricts influenza A virus replication by perturbing viral polymerase activity.

Researchers studying NAD+ published a paper titled "The nicotinamide phosphoribosyltransferase inhibitor FK866 restricts influenza A virus replication by perturbing viral polymerase activity." in Journal of virology (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Chembiochem : a European journal of chemical biology · 2026-06-15

Semi-Rational Engineering of Formate Dehydrogenase Reveals Loop Dynamics as a Key Determinant of Thermostability.

Researchers studying NAD+ published a paper titled "Semi-Rational Engineering of Formate Dehydrogenase Reveals Loop Dynamics as a Key Determinant of Thermostability." in Chembiochem : a European journal of chemical biology (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

International immunopharmacology · 2026-06-15

DHRS9 knockdown attenuates severe acute pancreatitis by inhibiting ferroptosis through the modulation of redox homeostasis and oxylipin metabolism.

Researchers studying NAD+ published a paper titled "DHRS9 knockdown attenuates severe acute pancreatitis by inhibiting ferroptosis through the modulation of redox homeostasis and oxylipin metabolism." in International immunopharmacology (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Anaerobe · 2026-06-15

(1)H-NMR metabolomic profiling of Methanobacterium and Methanosarcina reveals unusual intracellular trimethylamine and acetamide production.

Researchers studying NAD+ published a paper titled "(1)H-NMR metabolomic profiling of Methanobacterium and Methanosarcina reveals unusual intracellular trimethylamine and acetamide production." in Anaerobe (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Marine pollution bulletin · 2026-06-15

Short-term plasticity and long-term transcriptomic rewiring under natural ocean acidification in an ecosystem-relevant sea urchin.

Researchers studying NAD+ published a paper titled "Short-term plasticity and long-term transcriptomic rewiring under natural ocean acidification in an ecosystem-relevant sea urchin." in Marine pollution bulletin (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Cancer research · 2026-06-15

Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.

Researchers studying THYMOSIN α-1 published a paper titled "Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells." in Cancer research (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: THYMOSIN-ALPHA-1

Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026-06-15

NAD(+) Metabolism Licenses Zygotic Genome Activation via PARP7-Mediated ADP-Ribosylation of UHRF1 in Mouse Early Embryos.

Researchers studying NAD+ published a paper titled "NAD(+) Metabolism Licenses Zygotic Genome Activation via PARP7-Mediated ADP-Ribosylation of UHRF1 in Mouse Early Embryos." in Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of environmental management · 2026-06-15

Electro-driven microbial conversion of waste carbon sources to polyhydroxyalkanoates: pathways, mechanisms, and prospects.

Researchers studying NAD+ published a paper titled "Electro-driven microbial conversion of waste carbon sources to polyhydroxyalkanoates: pathways, mechanisms, and prospects." in Journal of environmental management (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Circulation. Heart failure · 2026-06-15

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.

Researchers studying SS-31 published a paper titled "Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model." in Circulation. Heart failure (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: SS-31

Contact dermatitis · 2026-06-15

Long-Term Risk of Allergic Contact Dermatitis in Children With Atopic Respiratory Disease When They Reach Adulthood.

Researchers studying NAD+ published a paper titled "Long-Term Risk of Allergic Contact Dermatitis in Children With Atopic Respiratory Disease When They Reach Adulthood." in Contact dermatitis (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Free radical biology & medicine · 2026-06-15

Environmental factors modulate the responsiveness and reversibility of the H(2)O(2)-induced inactivation of GAPDH.

Researchers studying NAD+ published a paper titled "Environmental factors modulate the responsiveness and reversibility of the H(2)O(2)-induced inactivation of GAPDH." in Free radical biology & medicine (2026 Jun 15). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Expert opinion on therapeutic targets · 2026-06-14

The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies.

Researchers studying NAD+ published a paper titled "The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies." in Expert opinion on therapeutic targets (2026 Jun 14). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biomolecular NMR assignments · 2026-06-12

NMR study of human macroPARPs domains: (1)H, (13)C and (15)N backbone and side-chain chemical shift assignments of hPARP9 macro domain 1 (MD1) in the apo and in the ADPr bound states.

Researchers studying NAD+ published a paper titled "NMR study of human macroPARPs domains: (1)H, (13)C and (15)N backbone and side-chain chemical shift assignments of hPARP9 macro domain 1 (MD1) in the apo and in the ADPr bound states." in Biomolecular NMR assignments (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of ethnopharmacology · 2026-06-12

Combining network pharmacology and transcriptomics to validate and explore Shenqiyichang decoction in treating colorectal cancer by NQO1 inhibition, ROS activation and Wnt/β-catenin signaling pathway.

Researchers studying NAD+ published a paper titled "Combining network pharmacology and transcriptomics to validate and explore Shenqiyichang decoction in treating colorectal cancer by NQO1 inhibition, ROS activation and Wnt/β-catenin signaling pathway." in Journal of ethnopharmacology (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Neurochemical research · 2026-06-12

Role of the P2X7-Nrf2 Pathway in Hyperalgesia Induced by Chronic Compression of the Dorsal Root Ganglion.

Researchers studying NAD+ published a paper titled "Role of the P2X7-Nrf2 Pathway in Hyperalgesia Induced by Chronic Compression of the Dorsal Root Ganglion." in Neurochemical research (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of ethnopharmacology · 2026-06-12

Inhibitory effects and molecular mechanisms of Aristolochic acids on human and rat placental 3β-hydroxysteroid dehydrogenases.

Researchers studying NAD+ published a paper titled "Inhibitory effects and molecular mechanisms of Aristolochic acids on human and rat placental 3β-hydroxysteroid dehydrogenases." in Journal of ethnopharmacology (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Metabolic engineering · 2026-06-12

Development of a Noncanonical Redox Cofactor Platform in Saccharomyces cerevisiae.

Researchers studying NAD+ published a paper titled "Development of a Noncanonical Redox Cofactor Platform in Saccharomyces cerevisiae." in Metabolic engineering (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Neurochemical research · 2026-06-12

β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NAD(+)-Depletion that Affects the Energy Metabolism of Cultured Primary Rat Astrocytes.

Researchers studying NAD+ published a paper titled "β-Lapachone-Induced Oxidative Stress Causes PARP-Dependent NAD(+)-Depletion that Affects the Energy Metabolism of Cultured Primary Rat Astrocytes." in Neurochemical research (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biological psychiatry · 2026-06-12

Sirtuin 2 Regulates Dorsal Hippocampal Actin Polymerization and Microtubule Acetylation-dependent EB3 Activation to Modulate Opioid Withdrawal-Induced Aversive Memory and Associative Learning.

Researchers studying NAD+ published a paper titled "Sirtuin 2 Regulates Dorsal Hippocampal Actin Polymerization and Microtubule Acetylation-dependent EB3 Activation to Modulate Opioid Withdrawal-Induced Aversive Memory and Associative Learning." in Biological psychiatry (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Plant physiology · 2026-06-12

Glycolysis Dominates Over Photorespiration in Governing Oxalate Accumulation in Rice.

Researchers studying NAD+ published a paper titled "Glycolysis Dominates Over Photorespiration in Governing Oxalate Accumulation in Rice." in Plant physiology (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Organic letters · 2026-06-12

Unspecific Peroxygenase Catalyzed Benzylic C-H Functionalization of diN-Heterocycles and Its Application.

Researchers studying NAD+ published a paper titled "Unspecific Peroxygenase Catalyzed Benzylic C-H Functionalization of diN-Heterocycles and Its Application." in Organic letters (2026 Jun 12). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Expert review of clinical pharmacology · 2026-06-11

Tirzepatide in type 1 diabetes: beyond mere weight loss.

Researchers studying GLP-1 / GLUCAGON DUAL AGONIST published a paper titled "Tirzepatide in type 1 diabetes: beyond mere weight loss." in Expert review of clinical pharmacology (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST

Science (New York, N.Y.) · 2026-06-11

The placental metabolic clock.

Researchers studying NAD+ published a paper titled "The placental metabolic clock." in Science (New York, N.Y.) (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of biotechnology · 2026-06-11

7,8-Dihydroxyflavone enhances recombinant proteins expression in CHO cells by modulating SIRT1 signalling to improve mitochondrial respiratory capacity and redox homeostasis.

Researchers studying NAD+ published a paper titled "7,8-Dihydroxyflavone enhances recombinant proteins expression in CHO cells by modulating SIRT1 signalling to improve mitochondrial respiratory capacity and redox homeostasis." in Journal of biotechnology (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Biochemistry · 2026-06-11

Mechanistic Insights into the Stimulation of Arabidopsis PARP2 Self-Parylation Catalytic Activity by DNA Breaks and PAR.

Researchers studying NAD+ published a paper titled "Mechanistic Insights into the Stimulation of Arabidopsis PARP2 Self-Parylation Catalytic Activity by DNA Breaks and PAR." in Biochemistry (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Science (New York, N.Y.) · 2026-06-11

Placental nicotinamide adenine dinucleotide modulates the timing of labor.

Researchers studying NAD+ published a paper titled "Placental nicotinamide adenine dinucleotide modulates the timing of labor." in Science (New York, N.Y.) (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Communications medicine · 2026-06-11

A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis.

Researchers studying GLP-1 / GLUCAGON DUAL AGONIST published a paper titled "A unimolecular GLP-1 and FGF21 dual agonist for treatment of metabolic dysfunction-associated steatohepatitis." in Communications medicine (2026 Jun 11). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GLUCAGON-DUAL-AGONIST

Journal of medicinal chemistry · 2026-06-10

Mixed Lineage Kinase Suppression in Triple-Negative Breast Cancer: Identification of a Dual Inhibitor Targeting MLK3 and NAMPT.

Researchers studying NAD+ published a paper titled "Mixed Lineage Kinase Suppression in Triple-Negative Breast Cancer: Identification of a Dual Inhibitor Targeting MLK3 and NAMPT." in Journal of medicinal chemistry (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Diabetes research and clinical practice · 2026-06-10

GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.

Researchers studying GLP-1 / GIP DUAL AGONIST published a paper titled "GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study." in Diabetes research and clinical practice (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: GLP1-GIP-DUAL-AGONIST

Cell host & microbe · 2026-06-10

NAD to the bone: How bacteria put phages under aRES-t … and how phages fight back.

Researchers studying NAD+ published a paper titled "NAD to the bone: How bacteria put phages under aRES-t … and how phages fight back." in Cell host & microbe (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

European journal of pharmacology · 2026-06-10

Poliumoside alleviates oxidative stress and improves mitochondrial function to alleviate ischemic stroke injury.

Researchers studying NAD+ published a paper titled "Poliumoside alleviates oxidative stress and improves mitochondrial function to alleviate ischemic stroke injury." in European journal of pharmacology (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-06-10

Organic acids induce plant defense responses and suppress root-knot nematodes in tomato via molecular mechanisms and molecular docking insights.

Researchers studying NAD+ published a paper titled "Organic acids induce plant defense responses and suppress root-knot nematodes in tomato via molecular mechanisms and molecular docking insights." in Scientific reports (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of agricultural and food chemistry · 2026-06-10

l-Malic Acid Enhances Intestinal Stem Cell Expansion and Barrier Function via the Sirt2/β-Catenin Signaling Pathway.

Researchers studying NAD+ published a paper titled "l-Malic Acid Enhances Intestinal Stem Cell Expansion and Barrier Function via the Sirt2/β-Catenin Signaling Pathway." in Journal of agricultural and food chemistry (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Communications biology · 2026-06-10

Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer's disease.

Researchers studying NAD+ published a paper titled "Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer's disease." in Communications biology (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Journal of biomolecular structure & dynamics · 2026-06-10

Changes in biophysical characteristics of NAD(P)H dependent YghA from E. coli due to variation in pH.

Researchers studying NAD+ published a paper titled "Changes in biophysical characteristics of NAD(P)H dependent YghA from E. coli due to variation in pH." in Journal of biomolecular structure & dynamics (2026 Jun 10). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Scientific reports · 2026-06-09

Comprehensive metabolomic profiling of Egyptian Salvia species reveals promising leads for chemopreventive and anti-inflammatory drug development: In vitro and In silico study.

Researchers studying NAD+ published a paper titled "Comprehensive metabolomic profiling of Egyptian Salvia species reveals promising leads for chemopreventive and anti-inflammatory drug development: In vitro and In silico study." in Scientific reports (2026 Jun 9). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS

Angewandte Chemie (International ed. in English) · 2026-06-09

Reprogramming NAD(P)(+)-Binding Proteins for Iminium Biocatalysis via a Synthetic NAD(+)-Type Cofactor.

Researchers studying NAD+ published a paper titled "Reprogramming NAD(P)(+)-Binding Proteins for Iminium Biocatalysis via a Synthetic NAD(+)-Type Cofactor." in Angewandte Chemie (International ed. in English) (2026 Jun 9). The paper is indexed by PubMed and represents the most current published evidence on this compound. Read the full abstract via the PubMed link.

▶ COMPOUND: NAD-PLUS